CD274 and neoplasm: Considering that the immunomodulatory ability of PD-1/PD-L1 occurs at the tumor site or peripheral tissue, anti-PD-1/PD-L1 antibody agents are used to inhibit tumor cell growth by activating effector T cells, regulatory T cells, and B cells in the late T cell-mediated immune response [14].